Today: 29 June 2026
Browse Category

NYSE:CVS 29 October 2025 - 25 December 2025

CVS Stock After the Bell (Dec. 24, 2025): CVS Health Dips in After‑Hours Holiday Trade—Key News, Forecasts, and What to Watch Before the Next Open

CVS Stock After the Bell (Dec. 24, 2025): CVS Health Dips in After‑Hours Holiday Trade—Key News, Forecasts, and What to Watch Before the Next Open

CVS Health closed at $79.12 on Dec. 24, up 1.38% in a holiday-shortened session with light volume. After-hours trading saw shares slip to $79.01. The stock remains below its 52-week high of $85.15. A new Philadelphia lawsuit named CVS Caremark in an insulin pricing case, and a False Claims Act dispute continues to hang over the company.
25 December 2025
··
Healthcare & Pharma Giants US Stocks: Week Ahead Outlook After Eli Lilly’s Retatrutide, CVS Guidance, Pfizer’s Obesity Deal, and J&J’s Talc Verdict (Updated Dec. 14, 2025)

Healthcare & Pharma Giants US Stocks: Week Ahead Outlook After Eli Lilly’s Retatrutide, CVS Guidance, Pfizer’s Obesity Deal, and J&J’s Talc Verdict (Updated Dec. 14, 2025)

Eli Lilly reported late-stage trial success for its obesity drug retatrutide, with patients losing 28.7% of body weight over 68 weeks. Pfizer re-entered the obesity drug market through a $150 million licensing deal with Yao Pharma. The FDA moved to accelerate review of Lilly’s oral GLP-1 pill, orforglipron, possibly advancing a decision to March. The Fed cut rates by 25 basis points and signaled new Treasury purchases.
14 December 2025
······
CVS Health Stock Surges on 2025–2026 Guidance: Key News, Forecasts and Analysis Since November 21, 2025

CVS Health Stock Surges on 2025–2026 Guidance: Key News, Forecasts and Analysis Since November 21, 2025

CVS Health shares have surged about 70–80% year-to-date in 2025, trading near $80.6 and lifting the company’s market value to just under $100 billion. Q3 revenue rose nearly 8% to $102.9 billion, but a $5.7 billion goodwill impairment drove a GAAP net loss of almost $4 billion. CEO David Joyner will become board chair. CVS reached a $37.8 million federal settlement over insulin pen dispensing.
11 December 2025
··
CVS Health (CVS) Stock Soars in 2025 on New Guidance, AI Push and Clinic Reset – Is the Turnaround Finally Real?

CVS Health (CVS) Stock Soars in 2025 on New Guidance, AI Push and Clinic Reset – Is the Turnaround Finally Real?

CVS Health raised its 2025–2026 profit outlook and launched an AI-driven engagement platform at its Investor Day in Hartford, sending shares up 2% to around $78 on December 10. The stock has surged nearly 80% year to date. CVS now expects at least $400 billion in 2025 revenue and adjusted EPS of $6.60–$6.70, above prior guidance. Management projects mid-teens adjusted EPS growth through 2028.
10 December 2025
··
CVS Stock Outlook: Fresh Legal Headlines, Analyst Upgrades and 2026 Forecast (December 6, 2025)

CVS Stock Outlook: Fresh Legal Headlines, Analyst Upgrades and 2026 Forecast (December 6, 2025)

CVS Health shares traded near $75.60 on December 6, 2025, after a strong rally and a series of legal settlements, including a $37.8 million insulin pen case and an $18.2 million False Claims Act settlement. A federal judge also ordered CVS Caremark to pay nearly $290 million for Medicare overcharges. Management raised 2025 profit guidance and projected double-digit earnings growth for 2026.
6 December 2025
CVS Health Stock on December 2, 2025: Insulin Settlement, Analyst Targets and What’s Next for NYSE: CVS

CVS Health Stock on December 2, 2025: Insulin Settlement, Analyst Targets and What’s Next for NYSE: CVS

CVS Health shares fell 1.9% to $77.62 on December 2, 2025, underperforming the S&P 500 and healthcare peers after news of a $37.76 million federal settlement over insulin-pen billing. Trading volume topped 7.7 million shares, above average. The stock remains up about 75–80% for the year but sits roughly 8–9% below its late October high. CVS did not admit liability in the settlement.
3 December 2025
···
CVS Health Stock in December 2025: Price, Forecast, Dividend and Whether the Rally Still Has Room to Run

CVS Health Stock in December 2025: Price, Forecast, Dividend and Whether the Rally Still Has Room to Run

CVS Health shares closed at $79.10 on December 1, 2025, down 1.6% and about 7% below their 52-week high. The stock is up nearly 79% year-to-date. Q3 revenue rose 7.8% to $102.9 billion, with adjusted EPS of $1.60 but a GAAP loss per share of –$3.13 due to a $5.7 billion non-cash goodwill impairment. CVS’s trailing P/E ratio spiked above 200 from the one-time charge.
2 December 2025
··
CVS Health Stock Today (NYSE: CVS): Institutional Buying, New Board Chair and Q3 Shock Shape Outlook – November 23, 2025

CVS Health Stock Today (NYSE: CVS): Institutional Buying, New Board Chair and Q3 Shock Shape Outlook – November 23, 2025

CVS Health stock closed Friday at $78.03, up nearly 80% from its 52-week low but still below its high. New 13F filings released Sunday show major institutions, including Handelsbanken Fonder AB and DNB Asset Management AS, increased their stakes in Q2. Institutional investors now hold over 80% of CVS shares. The company is also restructuring its primary care and PBM operations.
23 November 2025
·
Thanksgiving 2025 Store Hours: Is Kroger Open? H‑E‑B Hours, Louisville Malls and Which Stores Are Closed

Thanksgiving 2025 Store Hours: Is Kroger Open? H‑E‑B Hours, Louisville Malls and Which Stores Are Closed

Kroger stores will open on Thanksgiving 2025 with reduced hours, closing by mid-afternoon; pharmacies remain closed. H-E-B will operate 6 a.m. to noon. Louisville malls and most national chains, including Walmart, Target, and Costco, will be closed. Meijer, Food Lion, Whole Foods, and several Albertsons stores will open but close early.
21 November 2025
··········
Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Novo Nordisk (NVO) Today — Nov. 12, 2025: WeightWatchers to Offer Wegovy Pill, Canada Eyes Ozempic Copies, and the Latest Stock Move

WeightWatchers plans to offer Novo Nordisk’s oral Wegovy in the U.S. after its expected 2026 launch. Sandoz says unbranded Ozempic could reach Canada by June 2026, intensifying price competition. CVS dropped Lilly’s Zepbound from its preferred list, keeping Wegovy, prompting Lilly to move employees off CVS plans. Novo Nordisk shares traded at $49.76 late Wednesday, up slightly.
12 November 2025
·····
1 2 3

Stock Market Today

  • Nintendo Shares Slide 26% in 3 Months - Is It a Buying Opportunity?
    June 28, 2026, 7:27 PM EDT. Nintendo's (TSE:7974) stock has slid about 26% over three months, with a year-to-date drop of 38%. The price-to-earnings (P/E) ratio stands at 17.9x, above the Japanese entertainment sector average of 15x but below the peer average of 22.1x and a fair estimated P/E of 26.5x. This suggests the stock is trading at a discount to its intrinsic value, supported by a discounted cash flow (DCF) valuation indicating a fair value of ¥9,335 versus the current ¥6,589. However, risks remain including potential underperformance in new game releases and competition in mobile and console gaming impacting margins and revenue growth. Investors are weighing if recent setbacks present a bargain or signal deeper challenges in Nintendo's growth outlook.

Latest articles

Trump-era loan caps could open door for private lenders in grad school market

Trump-era loan caps could open door for private lenders in grad school market

29 June 2026
July 1 federal loan caps slash Grad PLUS access, forcing many graduate and professional students to seek private loans; Sallie Mae projects up to 70% origination growth over several years, while SoFi reports record student-loan volume—investors now face a real-time test of how much demand shifts to private lenders as federal limits hit.
IREN Limited (NASDAQ:IREN) slides as Warriors badge faces AI revenue test

IREN Limited (NASDAQ:IREN) slides as Warriors badge faces AI revenue test

29 June 2026
IREN Limited (NASDAQ:IREN) plunged 21.3% to $47.21 over five straight down days despite announcing a record $50M+ annual Warriors jersey deal, as investors focused on the company’s not fully contracted $4.4B target ARR and high short interest at 19.74% of float, with Friday’s close near the lowest analyst target.
Go toTop